More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
Startup vendor FIRE1 completed patient enrollment in its U.S. early feasibility study for a heart failure remote monitoring device that directly measures fluid volume inside the IVC.
Cerebral protection devices, designed to limit the risk of stroke during transcatheter aortic valve replacement, may be especially helpful when patients undergo valve-in-valve TAVR.
